NEI Research News

The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

A Northwestern Medicine study in mice has identified new treatment targets for glaucoma, including preventing a severe pediatric form of glaucoma, as well as uncovering a possible new class of therapy for the most common form of glaucoma in adults.

Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals.

By temporarily suspending retinal activity in the non-amblyopic eye of animal models, neuroscientists restrengthened the visual response in the amblyopic eye, even at ages after the critical period when patch therapy fails.

Researchers have developed a new gene therapy that could eventually provide an alternative treatment for Fuchs’ endothelial corneal dystrophy, a genetic eye disease affecting roughly one in 2,000 people globally.

Two translational studies at the Vanderbilt Eye Institute are targeting photoreceptors and retinal ganglion cells (RGCs) to restore vision through regeneration of the retina. The research is funded by the NEI Audacious Goals Initiative.

New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.

Research from the University of Utah explains why people with genetic variants may develop age-related macular degeneration (AMD) and identifies a potential therapeutic pathway for slowing disease progression.

Researchers at UAB have discovered a small molecule inhibitor that dampens the potent drivers of uveal melanoma.